Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.39 |
| ▸ | CNR2 | P34972 | 10/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 3/20 | 0.36 |
| ▸ | RARA | P10276 | 1/20 | 0.36 |
| ▸ | RARG | P13631 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4293874 | 0.91 | RARB (0.37) | CNR1CNR2RARBRARARARG | |
| SCHEMBL4295481 | 0.85 | SPHK1 (0.48) | SPHK1EPHX1EPHX2 | |
| SCHEMBL4294005 | 0.85 | SPHK1 (0.48) | SPHK1EPHX1EPHX2 | |
| SCHEMBL4296078 | 0.84 | RARB (0.53) | SPHK1RARBRARARARGCCR2 | |
| SCHEMBL4300197 | 0.81 | CNR2 (0.37) | CNR1CNR2SPHK1CCR2EPHX1 | |
| SCHEMBL4288628 | 0.81 | CNR2 (0.37) | CNR1CNR2SPHK1CCR2EPHX1 | |
| SCHEMBL5809968 | 0.80 | CNR2 (0.31) | CNR1CNR2 | |
| SCHEMBL4293736 | 0.79 | RARB (0.53) | SPHK1RARBRARARARGEPHX1 | |
| SCHEMBL4293953 | 0.79 | RARB (0.53) | SPHK1RARBRARARARGEPHX1 | |
| SCHEMBL4291859 | 0.78 | S1PR1 (0.52) | SPHK1EPHX1EPHX2PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | claimed |
| WO-2006043149-A9 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET SOC CIV (FR) | 2006-08-10 | — | — | WO | claimed |
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
| WO-2006043149-A9 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET SOC CIV (FR) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006043149-A2 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET (FR) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | S1PR2, S1PR1, S1PR5 | CNR1 27/4885CNR2 25/4885SPHK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.